The role of interferon in hepatitis B therapy

Current Hepatitis Reports

Volumn 9, Issue 4, 2010, Pages 231-238

  Rijckborst, Vincent ^a   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antiviral therapy; HBV; Interferon; Nucleos(t)ide analogues

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; CIRCULAR DNA; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELBIVUDINE; TENOFOVIR; VIRUS DNA; VIRUS PROTEIN; VIRUS RNA;

AGITATION; ANOREXIA; ANTIGEN PRESENTATION; BONE MARROW SUPPRESSION; CELL ACTIVATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DEPRESSION; DRUG COST; DRUG TOLERABILITY; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEPATITIS; HEPATITIS B; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INDIVIDUALIZATION; INJECTION SITE REACTION; MEDICAL DECISION MAKING; MYALGIA; NATURAL KILLER CELL; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTION; REVIEW; SEROCONVERSION; SIDE EFFECT; SLEEP DISORDER; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNNECESSARY PROCEDURE;

EID: 77958099979     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-010-0055-1     Document Type: Review

References (50)

1. YF Liaw CM Chu 2009 Hepatitis B virus infection Lancet 373 582 92 10.1016/S0140-6736(09)60207-5 19217993 1:CAS:528:DC%2BD1MXhvFGltLk%3D
2. F Zoulim S Locarnini 2009 Hepatitis B virus resistance to nucleos(t)ide analogues Gastroenterology 137 1593 1608 10.1053/j.gastro.2009.08.063 19737565 1:CAS:528:DC%2BD1MXhsVyhsb%2FN
3. WG Cooksley T Piratvisuth SD Lee, et al. 2003 Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B J Viral Hepat 10 298 305 10.1046/j.1365-2893.2003.00450.x 12823597 1:STN:280:DC%2BD3szksVOquw%3D%3D (Pubitemid 36801917)
4. European Association for the Study of the Liver 2009 EASL Clinical Practice Guidelines: management of chronic hepatitis B J Hepatol 50 227 242 10.1016/j.jhep.2008.10.001
5. AS Lok BJ McMahon 2009 Chronic hepatitis B: update 2009 Hepatology 50 661 662 10.1002/hep.23190 19714720
6. SJ Hadziyannis D Vassilopoulos 2001 Hepatitis B e antigen-negative chronic hepatitis B Hepatology 34 617 624 10.1053/jhep.2001.27834 11584355 1:STN:280:DC%2BD3Mrjs1Srug%3D%3D (Pubitemid 32927983)
7. S Locarnini 2004 Molecular virology of hepatitis B virus Semin Liver Dis 24 Suppl 1 3 10 10.1055/s-2004-828672 15192795 1:CAS:528:DC%2BD2cXlvVensb4%3D
8. JJ Feld DK Wong EJ Heathcote 2009 Endpoints of therapy in chronic hepatitis B Hepatology 49 S96 S102 10.1002/hep.22977 19399800 1:CAS:528:DC%2BD1MXlvFKqsL0%3D
9. G Fattovich N Olivari M Pasino, et al. 2008 Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years Gut 57 84 90 10.1136/gut.2007.128496 17715267 1:STN:280:DC%2BD2sjltlyksQ%3D%3D
10. C Niederau T Heintges S Lange, et al. 1996 Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B N Engl J Med 334 1422 1427 10.1056/NEJM199605303342202 8618580 1:STN:280:DyaK283hvVyhtw%3D%3D (Pubitemid 26157437)
11. M van Zonneveld P Honkoop BE Hansen, et al. 2004 Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B Hepatology 39 804 810 10.1002/hep.20128 14999700 1:CAS:528:DC%2BD2cXjtlaiu70%3D (Pubitemid 38337661)
12. CJ Chen HI Yang J Su, et al. 2006 Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 65 73 10.1001/jama.295.1.65 16391218 1:CAS:528:DC%2BD28XhtlKqtQ%3D%3D (Pubitemid 43042691)
13. UH Iloeje HI Yang J Su, et al. 2006 Predicting cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterology 130 678 686 10.1053/j.gastro.2005.11.016 16530509 (Pubitemid 43374518)
14. G Fattovich F Bortolotti F Donato 2008 Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors J Hepatol 48 335 352 10.1016/j.jhep.2007.11.011 18096267 1:CAS:528: DC%2BD1cXlsF2isg%3D%3D
15. M Peters 1996 Actions of cytokines on the immune response and viral interactions: an overview Hepatology 23 909 916 10.1002/hep.510230436 8666349 1:CAS:528:DyaK28XisFygtLo%3D
16. A Craxi WG Cooksley 2003 Pegylated interferons for chronic hepatitis B Antiviral Res 60 87 89 10.1016/j.antiviral.2003.08.015 14638403 1:CAS:528:DC%2BD3sXpt1eqsro%3D (Pubitemid 37452451)
17. DK Wong AM Cheung K O'Rourke, et al. 1993 Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis Ann Intern Med 119 312 323 8328741 1:STN:280:DyaK3szhvFWqsQ%3D%3D
18. HL Janssen M van Zonneveld H Senturk, et al. 2005 Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 123 129 10.1016/S0140-6736(05)17701-0 15639293 1:CAS:528:DC%2BD2MXhvF2gsQ%3D%3D (Pubitemid 40091801)
19. GK Lau T Piratvisuth KX Luo, et al. 2005 Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2682 2695 10.1056/NEJMoa043470 15987917 1:CAS:528:DC%2BD2MXls1SktL8%3D (Pubitemid 41007823)
20. EH Buster HJ Flink Y Cakaloglu, et al. 2008 Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b Gastroenterology 135 459 467 10.1053/j.gastro.2008.05.031 18585385 1:CAS:528:DC%2BD1cXhtVCqsL%2FK This report describes the durability of HBeAg loss induced by PEG-IFN therapy for HBeAg-positive CHB.
21. SK Fung AS Lok 2004 Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 40 790 792 15382157
22. A Erhardt D Blondin K Hauck, et al. 2005 Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D Gut 54 1009 1013 10.1136/gut.2004.060327 15951551 1:CAS:528:DC%2BD2MXmsFKqtrg%3D (Pubitemid 40873918)
23. CT Wai CJ Chu M Hussain, et al. 2002 HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C Hepatology 36 1425 1430 12447868 1:CAS:528:DC%2BD38Xps1ylurk%3D
24. EH Buster BE Hansen GK Lau, et al. 2009 Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa Gastroenterology 137 2002 2009 10.1053/j.gastro.2009.08.061 19737568 1:CAS:528:DC%2BD1MXhs1SisrzJ This important study provides a decision rule for prediction of response to PEG-IFN therapy at baseline based on the two largest PEG-IFN trials for HBeAg-positive CHB.
25. MJ ter Borg M van Zonneveld S Zeuzem, et al. 2006 Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response Hepatology 44 721 727 10.1002/hep.21302 16941701 1:CAS:528:DC%2BD28XhtVeqt7bK (Pubitemid 44433729)
26. BE Hansen EH Buster EW Steyerberg, et al. 2010 Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment J Med Virol 82 1135 1142 10.1002/jmv.21778 20513075 1:CAS:528:DC%2BC3cXns1Citbo%3D
27. T Nguyen P Desmond S Locarnini 2009 The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B Hepatol Int 3 S5 S15 10.1007/s12072-009-9149-7
28. MW Fried T Piratvisuth GK Lau, et al. 2008 HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B Hepatology 47 428 434 10.1002/hep.22065 18220290 1:CAS:528:DC%2BD1cXitF2ltbk%3D The potential of quantitative HBeAg for predicting response to PEG-IFN therapy in HBeAg-positive patients is investigated in this study. (Pubitemid 351280710)
29. B Werle-Lapostolle S Bowden S Locarnini, et al. 2004 Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy Gastroenterology 126 1750 1758 10.1053/j.gastro.2004. 03.018 15188170 1:CAS:528:DC%2BD2cXlsFaqs78%3D (Pubitemid 38736340)
30. K Wursthorn M Lutgehetmann M Dandri, et al. 2006 Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B Hepatology 44 675 684 10.1002/hep.21282 16941693 1:CAS:528:DC%2BD28XhtVeqt7bM (Pubitemid 44433724)
31. GKK Lau P Marcellin M Brunetto, et al. 2009 On-treatment monitoring of HBsAg levels to predict response to peginterferon alfa-2a in patients with HBeAg-positive chronic hepatitis B J Hepatol 50 S333 10.1016/S0168-8278(09) 60919-3
32. SJ Hadziyannis 2007 Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients Expert Opin Investig Drugs 16 777 786 10.1517/13543784.16.6.777 17501691 1:CAS:528:DC%2BD2sXltlOju7g%3D (Pubitemid 46882353)
33. P Marcellin GK Lau F Bonino, et al. 2004 Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 1206 1217 10.1056/NEJMoa040431 15371578 1:CAS:528:DC%2BD2cXns12rsr0%3D (Pubitemid 39296307)
34. P Marcellin F Bonino GK Lau, et al. 2009 Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a Gastroenterology 136 2169 2179 10.1053/j.gastro.2009.03.006 19303414 1:CAS:528:DC%2BD1MXotVeqtbw%3D This important study describes the durability of response to PEG-IFN therapy in HBeAg-negative patients.
35. F Bonino P Marcellin GK Lau, et al. 2007 Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B Gut 56 699 705 10.1136/gut.2005.089722 17127704 1:CAS:528:DC%2BD2sXlvVKlt7Y%3D (Pubitemid 46662938)
36. P Farci P Marcellin ZM Lu, et al. 2005 On-treatment predictors of sustained biochemical and virological response in patients with HBeAg-negative chronic hepatitis B (CHB) treated with peginterferon alpha-2a (40 kDa) (Pegasys(R)) J Hepatol 42 S175
37. MR Brunetto F Moriconi F Bonino, et al. 2009 Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B Hepatology 49 1141 1150 10.1002/hep.22760 19338056 1:CAS:528:DC%2BD1MXkslSqu7g%3D This study investigates the role of quantitative HBsAg in prediction of sustained response to PEG-IFN therapy.
38. R Moucari V Mackiewicz O Lada, et al. 2009 Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients Hepatology 49 1151 1157 10.1002/hep.22744 19115222 1:CAS:528:DC%2BD1MXkslSqu7k%3D
39. V Rijckborst BE Hansen Y Cakaloglu, et al. 2010 Early prediction of sustained response to peginterferon alfa-2a in HBeAg-negative patients: The role of on-treatment HBsAg and HBV DNA levels J Hepatol 52 S4 S5 10.1016/S0168-8278(10)60010-4
40. P Piccolo I Lenci L Demelia, et al. 2009 A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B Antivir Ther 14 1165 1174 10.3851/IMP1466 20032546 1:CAS:528:DC%2BC3cXitVyqu78%3D
41. Rijckborst V, Ter Borg MJ, Cakaloglu Y, et al.: A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010, 105:1762-1769.
42. SK Sarin A Sood M Kumar, et al. 2007 Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B Am J Gastroenterol 102 96 104 10.1111/j.1572-0241.2006.01006.x 17266689 1:CAS:528:DC%2BD2sXhvVOms7Y%3D (Pubitemid 46072048)
43. HL Chan VW Wong AM Chim, et al. 2007 Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B Antivir Ther 12 815 823 17713165 1:CAS:528:DC%2BD2sXpslOlsLY%3D
44. P Lampertico E Del Ninno M Vigano, et al. 2003 Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy Hepatology 37 756 763 10.1053/jhep.2003.50148 12668967 1:CAS:528:DC%2BD3sXjt1Wltbo%3D (Pubitemid 36397385)
45. P Lampertico M Vigano G Di Costanzo, et al. 2010 Extended (2 years) treatment with peginterferon alfa-2a [40 kD] improves sustained response rates in genotype D patients with HBeAg negative chronic hepatitis B J Hepatol 52 S45 10.1016/S0168-8278(10)60100-6
46. M van Zonneveld HJ Flink E Verhey, et al. 2005 The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation Aliment Pharmacol Ther 21 1163 1171 10.1111/j.1365-2036.2005.02453.x 15854180 1:CAS:528:DC%2BD2MXltVWkur8%3D (Pubitemid 40646544)
47. EH Buster BE Hansen M Buti, et al. 2007 Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis Hepatology 46 388 394 10.1002/hep.21723 17604363 1:CAS:528: DC%2BD2sXhtVSmu7nJ (Pubitemid 47344773)
48. HL Janssen JT Brouwer F Nevens, et al. 1993 Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep) BMJ 306 107 108 10.1136/bmj.306.6870.107 8435602 1:STN:280: DyaK3s7mvFWkug%3D%3D
49. D Shouval CL Lai TT Chang, et al. 2009 Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy J Hepatol 50 289 295 10.1016/j.jhep.2008.10.017 19070393 1:CAS:528:DC%2BD1MXntVGhtg%3D%3D
50. JL Dienstag J Cianciara S Karayalcin, et al. 2003 Durability of serologic response after lamivudine treatment of chronic hepatitis B Hepatology 37 748 755 10.1053/jhep.2003.50117 12668966 1:CAS:528:DC%2BD3sXjt1Wltb0%3D (Pubitemid 36397384)